Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Current role of endoscopic cholangioscopy

Derdeyn, Joliena; Laleman, Wima,b

Current Opinion in Gastroenterology: September 2018 - Volume 34 - Issue 5 - p 301–308
doi: 10.1097/MOG.0000000000000457
ENDOSCOPY: Edited by Anthony N. Kalloo

Purpose of review Every year more than one million people worldwide undergo an endoscopic retrograde cholangiopancreatography (ERCP) for disorders of the bile duct system. This review aims to discuss recent clinical data with regard to single-operator peroral cholangioscopy (POC).

Recent findings Innovations and technical optimizations of POC devices have extended diagnostic and therapeutic options for patients with complex biliary disease. Most of the currently available clinically relevant data are obtained with the single-operator peroral cholangioscopy (SOC)-system SpyGlass, which in a period of a decade has evolved further to a digital platform with increasing applicability, usefulness and cost-effectiveness.

Summary POC allows endoscopists to treat patients with complicated diseases of the gallbladder, liver, biliary tract, and pancreas better. In recent years, this technique was optimized to overcome prior limitations. The implementation of the single-operator SpyGlass Digital System in daily practice becomes a reality. We make an overview of the history of cholangioscopy, the technical evolution, and usefulness of this platform and take a look at its economic impact.

aDepartment of Gastroenterology & Hepatology, Section of Liver and Biliopancreatic Disorders, University Hospital, Gasthuisberg

bDepartment of Chronic Diseases, Metabolism & Ageing (CHROMETA), Division of Hepatology, KU Leuven, Leuven, Belgium

Correspondence to Wim Laleman, MD, PhD, Department of Gastroenterology & Hepatology, Section of Liver and Biliopancreatic Disorders, University Hospital Gasthuisberg, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel: +32 16 34 46 26; +32 16 34 42 99; fax: +32 16 34 43 87; e-mail: wim.laleman@uzleuven.be

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.